Group 1 - The Hebei Shijiazhuang Intermediate People's Court has announced a representative lawsuit registration notice regarding ST Xudong, indicating that 11 investors have initiated legal action for securities misrepresentation [1] - The court's announcement specifies the rights holders' scope, registration period, and methods for investors who purchased ST Xudong shares between February 15, 2016, and July 5, 2024 [1] - Investors who meet the criteria can register their claims by January 8, 2026, through the designated online platform [1] Group 2 - The China Securities Investor Service Center will continue to support the lawsuit and actively promote the representative lawsuit process, providing updates through various channels [2]

Core Viewpoint - The China Securities Investor Service Center supports 11 investors in a lawsuit against ST Xudong for false statements, which has been accepted by the Shijiazhuang Intermediate People's Court [1][2]. Group 1: Lawsuit Details - The Shijiazhuang Intermediate People's Court issued a public announcement on December 9, 2025, regarding the representative lawsuit, detailing the scope of rights holders, registration period, and registration methods [1][2]. - The rights holders are defined as investors who purchased Dongxu Optoelectronics stock (original stock code: 000413) through public bidding from February 15, 2016, to July 5, 2024, and still held the stock at the close of trading on July 5, 2024, with similar claims [1][2]. Group 2: Registration Process - Eligible investors must register their claims by January 8, 2026, through the Shijiazhuang Intermediate People's Court's securities dispute litigation intelligent review platform [1][2]. - The court's consultation phone number is provided for inquiries [1][2]. Group 3: Ongoing Support - The China Securities Investor Service Center will continue to fulfill its responsibilities in supporting the lawsuit and will provide updates on the litigation progress through various platforms [2][3].

Core Viewpoint - The ongoing legal dispute involves investors and Nanjing Panda Electronics Co., Ltd. regarding false statements in securities, with potential compensation for affected investors [1][2][4]. Group 1: Company Performance and Disclosures - On January 30, 2024, Nanjing Panda announced an estimated net profit for 2023 of approximately CNY 16.19 million to CNY 24.29 million, with a net profit excluding non-recurring gains and losses estimated between CNY -3.27 million to CNY 4.82 million [1][4]. - However, the actual net profit reported on March 29, 2024, was CNY -237.86 million, and the net profit excluding non-recurring gains and losses was CNY -257.01 million, indicating a significant discrepancy between the forecast and actual results [1][4]. Group 2: Legal Implications and Investor Rights - According to new judicial interpretations regarding false statements in securities, investors who suffered losses due to Nanjing Panda's alleged false disclosures can file lawsuits for compensation, which may include losses from price differences, commissions, and stamp duty [2][4]. - Investors who purchased Nanjing Panda shares between January 31, 2024, and March 28, 2024, and held them until the market close on March 28, 2024, are eligible to seek compensation, with the amount to be determined by the court [2][4].

Core Viewpoint - The ongoing legal case against Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd. (ST Nuotai) involves allegations of false statements in securities, with investors seeking compensation for losses incurred due to these misrepresentations [1][4]. Group 1: Allegations of False Statements - Nuotai Biopharmaceutical's 2021 annual report contained false records, including a reported business income of 30 million yuan from a technology transfer to Zhejiang Huabei, which lacked the financial capability to pay for it [1][4]. - The technology transfer was deemed to lack commercial substance, leading to an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, representing 20.64% of the total profit disclosed for that period [1][4]. Group 2: Misrepresentation in Public Offering Documents - On December 12, 2023, Nuotai Biopharmaceutical issued a prospectus for a convertible bond offering of 434 million yuan, which included false financial information from the 2021 annual report [2][5]. - The prospectus disclosed that the inflated revenue and profit figures were included in the financial accounting information, constituting significant false content [2][5]. Group 3: Investor Compensation - Investors who purchased Nuotai Biopharmaceutical shares between April 28, 2022, and October 23, 2024, and still held them as of the latter date are eligible to seek compensation, subject to court verification [3][6]. - Required documentation for claims includes securities account information, stock reconciliation statements from April 1, 2022, to the present, and contact information [3][6].

公告显示，证监会查明，三七互娱存在以下违法事实： （一）2014 年至 2020 年年报披露的股东持股情 况存在虚假记载。（二）2018 年年度报告未披露收购江苏极光股权事项为关联交易，存在重大遗漏。 （三）三七互娱 2020 年间接收购广州三七股权事项为关联交易，2020 年 12 月 7 日披 露的临时公告虚 假记载、2020 年年度报告存在重大遗漏。（四）2018 年至 2021 年年报未披露与海南力源等公司发生的 关联交易，存在重大遗漏。证监会决定： 对三七互娱责令改正，给予警告，并处以 900 万元罚款；对 相关责任人员给予警告，并各处以罚款。 根据《证券法》、虚假陈述司法解释，上市公司等因信息披露违法导致投资者权益受损，受损投资者可 以依法起诉索赔，索赔范围包括：投资差额、佣金、印花税损失等。 "我们正在分批代理投资者起诉。"厉健律师表示，根据司法解释，暂定：在2015年3月31日至2023年6月 27日期间买入三七互娱股票，并在2023年6月27日收盘时还持有该股票的受损投资者，可索赔。索赔条 件以法院认定为准。（三七互娱维权入口） 投资者索赔需提供证券开户信息查询单原件、股票对账单原件（201 ...

Core Viewpoint - The ongoing legal case against Guangdong Huatie Tongda High-speed Equipment Co., Ltd. (*ST Huatie) regarding securities false statements is set to proceed, with a court hearing scheduled for December 10, 2024 [1][3]. Group 1: Legal Proceedings - The Guangzhou Intermediate People's Court will hear the case involving *ST Huatie, which has been under scrutiny for alleged securities fraud [1][3]. - Investors have the opportunity to file claims for damages due to the company's false statements, with the statute of limitations for claims still open [1][3]. Group 2: Company Violations - The Guangdong Securities Regulatory Commission has identified significant violations in *ST Huatie's financial disclosures, including false records in the 2020 and 2021 annual reports and failure to disclose related party transactions in multiple annual reports from 2019 to 2022 [4][5]. Group 3: Investor Compensation - Investors who purchased *ST Huatie shares between April 26, 2019, and April 28, 2023, and held them until the latter date are eligible for compensation, despite the company's delisting [6]. - Compensation claims can include losses from investment differences, commissions, and stamp duty, with specific documentation required for filing [6].

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、案件已立案审理 上海易连收到的处罚决定与审计机构立信中联收到的罚单，意味着围绕上海易连持续数年的财务造假与 审计失职案件，在2025年迎来了阶段性了结。 关于投资者诉上海易连证券虚假陈述一案，上海沪紫律师事务所刘鹏律师团队已多次递交案件至上海金 融法院立案审理，已有案件开庭审理。（刘鹏律师专栏） 回溯此案，2025年1月8日，上海易连收到中国证监会上海监管局出具的《行政处罚决定书》。不过也因 该公司违法违规引发了大批投资者的索赔。 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 在一系列财务造假行为被揭穿后，上海易连的股票从主板退市。曾经被粉饰的财报背后，是公司内部控 制的系统性失灵和审计机构的多重失职。刘鹏律师提示虽公司退市， ...

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、部分案件已递交立案 上海沪紫律师事务所刘鹏律师团队代理的投资者诉亿利洁能证券虚假陈述案，已陆续递交法院立案审 理。值得注意的是该公司已于2024年7月18日终止上市。（刘鹏律师专栏） 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、部分案件已递交立案 在退市一年后，2025年9月，内蒙古证监局公布了对亿利洁能的行政处罚决定，因长达8年的财务造假行 为被处以巨额罚款。 依据相关法律法规，符合于2017年4月18日-2024年4月23日期间买入，并在2024年4月24日之后卖出或仍 持有而亏损的即可参与维权。对于权益受损的投资者而言，唯有通过法律途径主动维权，才能弥补部分 损失，维护自身合法权益。（ST亿利维权入口） 二、连续八 ...

Core Viewpoint - China Chemical is involved in a lawsuit related to the financial fraud case of Kangde Xin, with potential claims amounting to 4.139 billion yuan from investors due to false statements made by Kangde Xin [1][5] Group 1: Legal Issues - China Chemical's subsidiary, Ningbo Engineering Co., received a lawsuit notification regarding securities fraud claims against Kangde Xin, with plaintiffs seeking compensation for investment losses [1][5] - The lawsuit claims that Kangde Xin should pay 4.139 billion yuan in damages, and other defendants are also requested to bear joint liability [1][5] - China Chemical has stated that its subsidiary was not aware of Kangde Xin's financial fraud and does not expect the lawsuit to materially impact its profits [1][5] Group 2: Financial Performance - China Chemical's total revenue has stagnated in recent years, with a reported revenue of 1,866.13 billion yuan in 2024, a year-on-year increase of 4.14% [9] - The company aims to achieve a total revenue of 1,950 billion yuan by 2025, requiring a significant increase in revenue in the fourth quarter of 2025 [3][11] - As of the first three quarters of 2025, China Chemical achieved a revenue of 1,363 billion yuan, representing a 1.15% year-on-year growth, completing 69.9% of its annual target [4][11] Group 3: Future Outlook - China Chemical plans to complete new contract amounts of 3,700 billion yuan and aims for a profit total of 76.8 billion yuan by 2025 [10] - The company has successfully completed a nylon new material project, which is expected to enhance production efficiency and market competitiveness [12] - The chairman of China Chemical expressed a commitment to significantly improve the company's quality and performance over the next five years [12]

根据证券虚假陈述新司法解释，上市公司、中介机构等因证券虚假陈述行为导致投资者权益受损，受损 投资者可以依法起诉索赔，索赔范围包括：投资差额、佣金、印花税损失。 公开信息显示，此前，已有投资者收到苏州市中级人民法院送达的一审判决结果，部分投资者获得胜 诉。 "我们已代理多批股民起诉索赔。"厉健律师表示，根据司法解释，暂定：在2017年3月10日至2023 年4月27日期间买入天沃科技股票，并在2023年4月27日收盘持有股票的受损股民，可索赔。能否获赔、 赔偿多少以法院认定为准。（天沃科技维权入口） 投资者索赔需提供证券开户信息查询单、股票对账单（2017年3月1日至今）、联系方式等。 【本文由浙江裕丰律师事务所厉健律师供稿，不代表新浪财经的立场。厉健律师，系中国法学会证券法 学研究会理事、中国证券业协会证券纠纷调解员，2009年荣获"浙江省优秀青年律师"称号。2003年至 今，厉健律师代理投资者告赢五粮液、大智慧等100余家上市公司并获赔，成效显著。其中，祥源文 化、赵薇案入选2019年度人民法院十大商事案例，杭萧钢构案入选2012年度"全国法院十大调解案例"， 辉丰股份案系江苏省首例证券纠纷普通代表人案。厉 ...